Hypertension
I'll start by reading the medical library skill, then search for comprehensive hypertension content.
Reading File
Now I'll run parallel searches across the library for hypertension content.
Finding Sources
Searching PubMed
"hypertension"[MeSH Terms] AND "management"[MeSH Terms]
Good. Now let me read the key hypertension sections in parallel from the most relevant sources.
Reading File
Reading File
Searching PubMed
"hypertension" AND "guidelines"
Excellent - there's a 2025 AHA/ACC guideline (PMID 40811516). Now let me get the detailed hypertension management content from Family Medicine textbook and fetch the guideline abstract.
Reading File
Reading Article
PMID: 40811516
Finding Sources
Now let me read the most relevant sections - the Hurst's Heart hypertension section and the Gynecology classification section in parallel.
Reading File
Finding Sources
Now let me pull the pharmacology section from Goodman & Gilman and the Goldman-Cecil hypertension treatment section.
Reading File
Reading File
Reading File
I now have excellent content. Let me read a bit more on pathophysiology, complications, and treatment targets from Hurst's Heart.
Reading File
Reading File
I now have comprehensive content to deliver a thorough response. Let me compile everything.
Hypertension: A Comprehensive Clinical Overview
Definition and Classification
Hypertension is one of the most common and consequential chronic diseases worldwide. Blood pressure (BP) classification follows the 2017 ACC/AHA Guidelines (and the updated 2025 AHA/ACC Guideline - PMID 40811516):
| Category | SBP | DBP |
|---|---|---|
| Normal | <120 mmHg | and <80 mmHg |
| Elevated | 120-129 mmHg | and <80 mmHg |
| Stage 1 Hypertension | 130-139 mmHg | or 80-89 mmHg |
| Stage 2 Hypertension | ≥140 mmHg | or ≥90 mmHg |
Accurate measurement requires ≥2 readings on ≥2 separate occasions. Children <13 years are classified by age-adjusted percentiles. CVD risk relates to BP in a continuous fashion with no threshold - even pre-hypertensive levels carry excess risk.
2025 Update: The 2025 AHA/ACC/AANP Hypertension Guideline replaces the 2017 guideline and is now a "living document" updated with evidence from 2015 onward. Note: an erratum was issued (PMID 42160500).
Epidemiology
- Hypertension affects approximately 1 in 3 adults in the United States.
- Black adults have significantly higher prevalence than White or Hispanic adults (age-adjusted data from NHANES 2017-2018).
- Hispanic paradox: Despite similar hypertension prevalence to White adults, Hispanic Americans have ~10% lower coronary heart disease and ~30% lower heart disease mortality than Whites.
- Overweight and obesity may account for up to 75% of essential hypertension - Fuster and Hurst's The Heart, 15th Edition, p. 222.
Risk Factors
Nonmodifiable
- Older age (strongest predictor)
- Male sex
- Race/ethnicity
- Rare genetic variants
- Low socioeconomic status / psychosocial stress
Modifiable
- Obesity/adiposity - abdominal obesity (waist ≥102 cm men, ≥88 cm women) independently raises hypertension risk (OR 1.51)
- Sedentariness / physical inactivity
- High sodium / low potassium diet
- Excessive alcohol intake
- Smoking
- Obstructive sleep apnea
- Diabetes mellitus (bidirectional relationship confirmed by Mendelian randomization)
Populations with hunter-gatherer lifestyles (e.g., the Tsimane of Bolivia) have near-zero age-related BP rise, confirming lifestyle dominance over genetics.
Pathophysiology
Primary (Essential) Hypertension (~90-95%)
No single identifiable cause. Key mechanisms:
- Renin-Angiotensin-Aldosterone System (RAAS) overactivation - Angiotensin II (AngII) causes vasoconstriction, sodium retention, and end-organ damage via AT1 receptors
- Sympathetic nervous system hyperactivity - increased cardiac output and peripheral vascular resistance
- Renal sodium retention - impaired pressure-natriuresis
- Vascular remodeling - structural changes in arterioles increasing resistance
- Kallikrein-Kinin System (KKS) dysfunction - decreased urinary kallikrein in hypertensive patients suggests a protective role of the KKS; inversely, ACE inhibitors attenuate nephrosclerosis partly via enhanced kinin activity - Brenner and Rector's The Kidney, p. 469
Secondary Hypertension (~5-10%)
Identifiable causes include:
- Renal artery stenosis (renovascular hypertension)
- Primary hyperaldosteronism
- Pheochromocytoma
- Obstructive sleep apnea
- Thyroid disorders
- Medication-induced (NSAIDs, oral contraceptives, sympathomimetics)
Complications (Target-Organ Damage)
Sustained elevated BP damages multiple organs:
| Organ System | Complications |
|---|---|
| Heart | LV hypertrophy, coronary artery disease, heart failure, AF |
| Brain | Stroke (ischemic & hemorrhagic), vascular dementia, TIA |
| Kidneys | Nephrosclerosis, CKD, proteinuria |
| Eyes | Hypertensive retinopathy |
| Vessels | Peripheral arterial disease (2.5x risk in men, 3.9x in women), aortic aneurysm |
Hypertension carries a 2.5-fold age-adjusted risk for PAD in men and 3.9-fold in women - Textbook of Family Medicine 9e, p. 701.
Evaluation
BP Measurement
- Office BP: ≥2 readings, ≥2 visits
- Home BP monitoring (HBPM): Preferred for detecting white-coat hypertension and masked hypertension, guiding therapy
- Ambulatory BP monitoring (ABPM): Gold standard for diagnosis
Initial Workup
- History: Symptoms, medications, lifestyle, family history, secondary causes
- Physical exam: Weight, fundoscopy, cardiac/renal exam
- Labs: BMP (creatinine, electrolytes, glucose), urinalysis with microalbumin, lipid panel, TSH
- ECG: LV hypertrophy assessment
Treatment
Lifestyle Modifications (First for Stage 1 without high CVD risk)
- Weight loss (most effective single intervention)
- DASH diet (high fruits/vegetables, low sodium, low saturated fat)
- Sodium restriction (<2.3 g/day)
- Increase potassium intake
- Regular aerobic exercise (150+ min/week)
- Limit alcohol
- Smoking cessation
Pharmacologic Treatment
First-Line Drug Classes (monotherapy or combinations): - Goodman & Gilman's The Pharmacological Basis of Therapeutics, p. 648
| Class | Key Agents | Notes |
|---|---|---|
| ACE Inhibitors | Lisinopril, ramipril, enalapril, perindopril | First-line for DM, CKD, proteinuria; cough in ~10% |
| ARBs | Losartan, valsartan, candesartan, telmisartan | Same profile as ACEi, no cough; do NOT combine with ACEi |
| Calcium Channel Blockers | Amlodipine, diltiazem, verapamil | Excellent for elderly, useful in angina |
| Thiazide Diuretics | Chlorthalidone, hydrochlorothiazide, indapamide | Chlorthalidone preferred over HCTZ for CV outcomes |
Second-Line Drugs: Beta-blockers, spironolactone, alpha-blockers, direct vasodilators.
Important: Beta-blockers are NOT recommended as initial therapy in uncomplicated hypertension - they are less effective than other first-line drugs for stroke prevention - Goldman-Cecil Medicine, p. 755. Never combine two RAAS inhibitors (ACEi + ARB) due to minimal additive BP benefit but high risk of renal impairment and hyperkalemia.
Combination Therapy
Most patients require 2+ drugs. Preferred combinations:
- ACEi/ARB + CCB (e.g., ramipril + amlodipine)
- ACEi/ARB + thiazide-like diuretic (e.g., telmisartan + chlorthalidone)
- A single pill with quarter-doses of four agents (irbesartan, amlodipine, indapamide, bisoprolol) is a validated low-dose quadruple strategy.
BP Targets
| Population | Target SBP |
|---|---|
| General adults | <130 mmHg |
| CKD (KDIGO 2021) | <130 mmHg |
| Elderly (>65 years) | <130 mmHg where tolerated |
| High-risk: CAD, DM, CKD | <130 mmHg |
Treatment of isolated systolic hypertension in the elderly reduces mortality, CV events, and dementia even beyond age 80, including in frail patients - Goldman-Cecil Medicine, p. 755.
Special Populations
Elderly
- Start with low doses; titrate slowly
- High risk of orthostatic and postprandial hypotension
- Monitor for hyponatremia with thiazides
- HBPM/ABPM essential to avoid overtreatment
Diabetes
- ACEi or ARB are first-line (proven renoprotective, cardioprotective)
- SGLT2 inhibitors provide additional BP reduction and CV/renal benefit
- 85% of diabetic patients in the ACCORD trial were on antihypertensives
Chronic Kidney Disease
- ACEi or ARB preferred (KDIGO 2021)
- Target SBP <130 mmHg
Pregnancy
- ACEi and ARBs are absolutely contraindicated in pregnancy (teratogenic)
- Use methyldopa, labetalol, or nifedipine
Peripheral Arterial Disease
- Beta-blockers are safe in PAD and do not worsen intermittent claudication (confirmed by meta-analysis) - Textbook of Family Medicine 9e, p. 701
- ACE inhibitors offer vascular protection beyond BP lowering alone (HOPE/EUROPA data)
Resistant Hypertension
Defined as BP above target despite 3 optimal-dose drugs (including a diuretic), or requiring 4+ drugs. Causes:
- Medication nonadherence
- Uncontrolled secondary hypertension (especially obstructive sleep apnea, primary aldosteronism)
- Volume overload
- Interfering substances (NSAIDs, stimulants, decongestants)
CPAP for obstructive sleep apnea significantly reduces BP in patients with resistant hypertension (HIPARCO trial). Add-on spironolactone is the most effective 4th drug.
Key Takeaways
- Hypertension is defined as SBP ≥130 or DBP ≥80 mmHg (ACC/AHA 2017/2025).
- Most patients (~90-95%) have essential (primary) hypertension with multifactorial causation.
- Lifestyle changes are first-line but most patients eventually need pharmacotherapy.
- First-line drugs: ACEi, ARBs, CCBs, thiazide diuretics. Beta-blockers are not first-line in uncomplicated hypertension.
- Never combine ACEi + ARB.
- A new 2025 AHA/ACC Guideline is now the authoritative reference, replacing the 2017 version.
Sources: Fuster and Hurst's The Heart 15e | Goldman-Cecil Medicine International Ed. | Goodman & Gilman's Pharmacological Basis of Therapeutics | Textbook of Family Medicine 9e | Brenner and Rector's The Kidney | 2025 AHA/ACC Hypertension Guideline (PMID 40811516)
This is a shared conversation. Sign in to Orris to start your own chat.